← Patent-cliff monitor small molecule JAKAFI XR RUXOLITINIB PHOSPHATE
Loss of exclusivity July 2034 latest FDA-listed patent expiry
Company Incyte → See this company's full patent-cliff portfolio Drug detail Brand name JAKAFI XR Active ingredient RUXOLITINIB PHOSPHATE Strength EQ 22MG BASE Dosage form TABLET, EXTENDED RELEASE Route ORAL Modality Small molecule FDA approval May 2026 Marketing status RX
Listed patents Patent Expires Type 11337927*PED July 2034 — 10874616*PED May 2034 — 11576865*PED May 2034 — 11576864*PED May 2034 — 11896717*PED May 2034 — 11337927 January 2034 use U-3226 11896717 November 2033 product 11576864 November 2033 use U-3226 11576865 November 2033 product 10874616 November 2033 product 8829013*PED December 2028 — 8722693*PED December 2028 — 10016429*PED December 2028 — 8822481*PED December 2028 — 11213528*PED December 2028 — 7598257*PED June 2028 — 8415362*PED June 2028 — 8829013 June 2028 use U-3228 10016429 June 2028 use U-3230 8822481 June 2028 use U-3226 8722693 June 2028 substance, product 11213528 June 2028 product 8415362 December 2027 substance, product 7598257 December 2027 substance, product 9079912 December 2026 use U-3226 9206187 December 2026 use U-3228 9814722 December 2026 use U-3230 11744832 December 2026 use U-3230 8530485 December 2026 product
Regulatory exclusivity Code Expires PED March 2029 ODE* September 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.